drugset

drugset / Trial / NCT03793140

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

NCT03793140 ↗

Phase 2 Active not recruiting 24 enrolled Memorial Sloan Kettering Cancer Center City of Hope Medical Center · collab George Washington University · collab M.D. Anderson Cancer Center · collab Massachusetts General Hospital · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test any good and bad effects of the study drug, CPI-613.

Timeline

Start: 2018-12-31
Primary completion: 2026-12
Completion: 2026-12

Publications

Steiner R, Nikolaenko L, Nair R, Seshan V, Thiruvengadam SK, Khan N, Abramson JS, Horwitz S, Matasar M, Owens C, Rodriguez Rivera II, Straus DJ, Pardee TS, Luther S, Saboukoulou S, Thet WS, Vemuri S, Noy A. Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial. Blood Adv. 2025 Nov 11;9(21):5556-5563. doi: 10.1182/bloodadvances.2025016168.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CPI-613	Small molecule	2500 mg/m2	Intravenous

Indications